Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline

JCO Oncol Pract. 2026 Jan;22(1):19-35. doi: 10.1200/OP-25-00133. Epub 2025 May 9.

Abstract

Purpose: To develop a clinical practice guideline and recommendations for symptom management of patients with well-differentiated grade 1 to grade 3 metastatic gastroenteropancreatic neuroendocrine tumors.

Methods: ASCO convened an Expert Panel to develop a clinical practice guideline by reviewing the literature for relevant guidelines, systematic reviews, randomized controlled trials (RCTs), and observational studies to develop recommendations for clinical practice.

Results: The literature review identified eight guidelines, 19 systematic reviews, and three RCTs that informed the development of guideline recommendations.

Recommendations: Recommendations are included for carcinoid syndrome, carcinoid heart disease and carcinoid crisis, and functional pancreatic neuroendocrine tumor syndromes. Recommendations are provided for surgical management, liver-directed therapy, and systemic therapy options, as well as palliative care. Limited guidance is provided for sequencing of interventions.Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.

Publication types

  • Practice Guideline

MeSH terms

  • Humans
  • Intestinal Neoplasms* / diagnosis
  • Intestinal Neoplasms* / pathology
  • Intestinal Neoplasms* / therapy
  • Neuroendocrine Tumors* / diagnosis
  • Neuroendocrine Tumors* / pathology
  • Neuroendocrine Tumors* / therapy
  • Pancreatic Neoplasms* / diagnosis
  • Pancreatic Neoplasms* / pathology
  • Pancreatic Neoplasms* / therapy
  • Stomach Neoplasms* / diagnosis
  • Stomach Neoplasms* / pathology
  • Stomach Neoplasms* / therapy

Supplementary concepts

  • Gastro-enteropancreatic neuroendocrine tumor